Skip to main content

Table 2 Systematic review of studies on furosemide and the outcome

From: Impact of furosemide on mortality and the requirement for renal replacement therapy in acute kidney injury: a systematic review and meta-analysis of randomised trials

Study Description of AKI cause Intervention Control arm Mortality by crude data and OR (95% CI) and p value Need for RRT by crude data and OR (95% CI) and p value
Badawy [16] ADCHF Treatment HDF Study group 5/20, control group 3/20; OR = 1.89 (95% CI 0.38–9.27); p = 0.43 NA
Bagshaw [17] AKI (ICU patients) Treatment Saline Study group 3/37, control group 5/36; OR = 0.55 (95% CI 0.12–2.48); p = 0.43 Study group 10/37, control group 10/36; OR = 0.96 (95% CI 0.34–2.69); p = 0.94
Barbanti [18] CIN (post TAVI) Prevention Saline Study group 1/56, control group 2/56; OR = 0.49 (95% CI 0.04–5.57); p = 0.57 NA
Bart [19] ADCHF Treatment Standard of care Study group 0/20, control group 1/20; OR = 0.32 (95% CI 0.01–8.26); p = 0.49 NA
Bart [20] ADCHF Treatment UF Study group 13/94, control group 16/94; OR = 0.78 (95% CI 0.35–1.73); p = 0.54 NA
Berthelsen [21] AKI (ICU patients with fluid overload) Treatment Furosemide + CRRT Study group 6/13, control group 2/7; OR = 2.14 (95% CI 0.3–15.36); p = 0.45 NA
Briguori [22] CIN (CKD patients) Prevention Bicarbonate + NAC NA Study group 1/146, control group 6/146; OR = 0.16 (95% CI 0.19–1.35); p = 0.09
Cantarovich [8] AKI (ICU + nephrology unit patients) Treatment Placebo Study group 59/166, control group 50/164; OR = 1.26 (95% CI 0.79–1.99); p = 0.33 NA
Costanzo [23] ADCHF Treatment UF Study group 11/100, control group 9/100; OR = 1.25 (95% CI 0.5–3.14); p = 0.64 NA
Costanzo [24] ADCHF Treatment UF Study group 11/95, control group 9/94; OR = 1.24 (95% CI 0.49–3.14); p = 0.65 NA
Costanzo [25] ADCHF Treatment UF Study group 1/114, control group 2/110; OR = 0.48 (95% CI 0.04–5.35); p = 0.55 NA
Dussol [26] CIN (CKD patients) Prevention Saline NA Study group 0/29, control group 0/30; OR = 1.03 (95% CI 0.2–53.83); p = 0.99
Grams [27] AKI (ALI) Treatment Low-dose furosemide Study group 64/169, control group 56/137; OR = 0.73 (95% CI 0.42–1.26); p = 0.26 Study group 45/169, control group 44/137; OR = 0.77 (95% CI 0.47–1.26); p = 0.29
Hanna [28] ADCHF Treatment UF Study group 4/17, control group 4/19; OR = 1.15 (95% CI 0.24–5.56); p = 0.86) NA
Lassnigg [7] AKI (post cardiac surgery) Prevention Saline Study group 4/41, control group 1/40; OR = 4.22 (95% CI 0.45–39.5); p = 0.21 Study group 2/41, control group 0/40; OR = 5.13 (95% CI 0.24–110.2); p = 0.29
Lim [29] AKI (post cardiac surgery) Prevention Placebo Study group 0/40, control group 0/39; OR = 0.98 (95% CI 0.19–50.4); p = 0.99 NA
Mahesh [30] AKI (post cardiac surgery) Prevention Saline Study group 1/21, control group 2/21; OR = 0.47 (95% CI 0.04–5.68); p = 0.56 Study group 1/21, control group 0/21; OR = 3.15 (95% CI 0.12–81.74); p = 0.49
Marenzi [31] CIN (CKD patients) Prevention Saline Study group 1/87, control group 3/83; OR = 0.31 (95% CI 0.03–3.04); p = 0.31 Study group 1/87, control group 3/83; OR = 0.31 (95% CI 0.03–3.04); p = 0.31
Marenzi [32] CHF Treatment UF Study group 11/29, control group 7/27 OR = 1.75 (95% CI 0.56–5.45); p = 0.34; NA
van der Voort [33] AKI (ICU patients post CVVHF) Treatment Placebo Study group 4/36, control group 4/35; OR = 0.97 (95% CI 0.22–4.22); p = 0.96 Study group 13/36, control group 7/35; OR = 2.26 (95% CI 0.77–6.6); p = 0.14
  1. ADCHF acute decompensated chronic heart failure, AHF acute heart failure, AKI acute kidney injury, ALI acute lung injury, ARF acute renal failure, CHF chronic heart failure, CIN contrast-induced nephropathy, CKD chronic kidney disease, CVVHF continuous venovenous hemofiltration, CRRT continuous renal replacement therapy, HDF hemodiafiltration, ICU intensive care unit, NA non-applicable, NAC N-acetylcysteine, OR odds ratio, RCT randomised controlled trial, TAVI transcatheter aortic valve implantation, UF ultrafiltration